Lund, T., Gundesen, M. T., Vangsted, A. J., Helleberg, C., Haukås, E., Silkjær, T., . . . Group, N. M. S. (2024). In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Nature Publishing Group.
Chicago Style (17th ed.) CitationLund, Thomas, et al. In Multiple Myeloma, Monthly Treatment with Zoledronic Acid Beyond Two Years Offers Sustained Protection Against Progressive Bone Disease. Nature Publishing Group, 2024.
MLA (9th ed.) CitationLund, Thomas, et al. In Multiple Myeloma, Monthly Treatment with Zoledronic Acid Beyond Two Years Offers Sustained Protection Against Progressive Bone Disease. Nature Publishing Group, 2024.
Warning: These citations may not always be 100% accurate.